How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 63.2 | 62.2 | 62.2 | 63.0 | 63.0 | 63.0 | -0.2 |
| Healthcare | 28.4 | 30.1 | 30.1 | 30.9 | 30.9 | 30.9 | +2.5 |
| Chemicals | 3.9 | 2.5 | 2.5 | 2.3 | 2.3 | 2.3 | -1.6 |
| Metal | 0.8 | 1.0 | 1.0 | 0.7 | 0.7 | 0.7 | -0.1 |
| Defence | · | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | -0.1 |
| Banking | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | -0.1 |
| Financial Services | 1.2 | · | · | · | · | · | · |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 13.26% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 7.97% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| APOLLOHOSP | Healthcare | 6.05% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| MAXHEALTH | Healthcare | 5.05% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| TORNTPHARM | Pharma | 4.84% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| CIPLA | Pharma | 4.43% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| DRREDDY | Pharma | 4.41% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| LAURUSLABS | Pharma | 4.21% | 9 | 9 | 3 | 3 | 1 | — | +29.2% |
| AUROPHARMA | Pharma | 3.84% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| MANKIND | Pharma | 3.39% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| COHANCE | Healthcare | 3.04% | 4 | 5 | 6 | 3 | 5 | — | +1.5% |
| NEULANDLAB | Healthcare | 3.03% | 8 | 10 | 7 | 4 | 1 | — | +30.4% |
| MEDANTA | Healthcare | 2.98% | 8 | 9 | 5 | 4 | 2 | — | +13.1% |
| ALKEM | Pharma | 2.92% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| LUPIN | Pharma | 2.82% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| FORTIS | Healthcare | 2.79% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| ABBOTINDIA | Pharma | 1.90% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| POLYMED | Healthcare | 1.52% | 6 | 6 | 5 | 6 | 6 | — | +18.6% |
| IPCALAB | Pharma | 1.50% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| ASTERDM | Healthcare | 1.35% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| SAILIFE | Healthcare | 1.32% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| PPLPHARMA | Pharma | 1.27% | 10 | 1 | 5 | 9 | 5 | Leader | +28.4% |
| SHAILY | Chemicals | 1.23% | 10 | 10 | 3 | 4 | 1 | Leader | +4.3% |
| HCG | Healthcare | 1.21% | 7 | 2 | 6 | 7 | 2 | — | +5.1% |
| SHILPAMED | Pharma | 1.15% | 8 | 9 | 6 | 1 | 1 | — | +72.0% |
| LINDEINDIA | Chemicals | 1.10% | 2 | 6 | 1 | 5 | 5 | — | -11.7% |
| GLENMARK | Pharma | 1.09% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| RAINBOW | Healthcare | 1.05% | 10 | 7 | 4 | 3 | 4 | — | +5.0% |
| BIOCON | Pharma | 0.95% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| GLAXO | Healthcare | 0.93% | 8 | 7 | 2 | 8 | 4 | — | +31.0% |
| SUPRIYA | Pharma | 0.92% | 6 | 10 | 5 | 8 | 3 | — | -5.5% |
| MEDPLUS | Pharma | 0.88% | 2 | 4 | 5 | 4 | 7 | — | -27.0% |
| ZYDUSLIFE | Pharma | 0.72% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| VENUSPIPES | Metal | 0.69% | 10 | 10 | 8 | 2 | 2 | — | +23.8% |
| SYNGENE | Healthcare | 0.61% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
| CAPLIPOINT | Pharma | 0.54% | 10 | 9 | 2 | 4 | 6 | — | +28.9% |
| BDL | Defence | 0.47% | 2 | 2 | 2 | 6 | 6 | — | +0.2% |
| YESBANK | Banking | 0.46% | 4 | 1 | 6 | 8 | 7 | — | -7.0% |
Performance · 4.8y
Over the last 4.8 years ₹100 in the fund grew to ₹182 (+82%), vs ₹150 for Nifty 500 (+50%) and ₹133 for Nifty 50 (+33%). Its relative-strength line ended at 137 vs Nifty 50 and 121 vs Nifty 500 — above 100, sustained outperformance.